Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Footnotes
  • Version history
  • Article usage
  • Citations to this article
Advertisement

Corrigendum Free access | 10.1172/jci.insight.130986

C3a and suPAR drive versican V1 expression in tubular cells of focal segmental glomerulosclerosis

Runhong Han, Shuai Hu, Weisong Qin, Jinsong Shi, Qin Hou, Xia Wang, Xiaodong Xu, Minchao Zhang, Caihong Zeng, Zhihong Liu, and Hao Bao

Find articles by Han, R. in: JCI | PubMed | Google Scholar

Find articles by Hu, S. in: JCI | PubMed | Google Scholar

Find articles by Qin, W. in: JCI | PubMed | Google Scholar

Find articles by Shi, J. in: JCI | PubMed | Google Scholar

Find articles by Hou, Q. in: JCI | PubMed | Google Scholar

Find articles by Wang, X. in: JCI | PubMed | Google Scholar

Find articles by Xu, X. in: JCI | PubMed | Google Scholar

Find articles by Zhang, M. in: JCI | PubMed | Google Scholar

Find articles by Zeng, C. in: JCI | PubMed | Google Scholar

Find articles by Liu, Z. in: JCI | PubMed | Google Scholar

Find articles by Bao, H. in: JCI | PubMed | Google Scholar

Published July 11, 2019 - More info

Published in Volume 4, Issue 13 on July 11, 2019
JCI Insight. 2019;4(13):e130986. https://doi.org/10.1172/jci.insight.130986.
© 2019 American Society for Clinical Investigation
Published July 11, 2019 - Version history
View PDF

Related article:

C3a and suPAR drive versican V1 expression in tubular cells of focal segmental glomerulosclerosis
Runhong Han, … , Zhihong Liu, Hao Bao
Runhong Han, … , Zhihong Liu, Hao Bao
C3a and suPAR synergistically induce versican V1 expression in tubular cells of focal segmental glomerulosclerosis by promoting transcription and splicing processes.
Research Article Nephrology

C3a and suPAR drive versican V1 expression in tubular cells of focal segmental glomerulosclerosis

  • Text
  • PDF
Abstract

Chronic tubulointerstitial injury impacts the prognosis of focal segmental glomerulosclerosis (FSGS). We found that the level of versican V1 was increased in tubular cells of FSGS patients. Tubular cell–derived versican V1 induced proliferation and collagen synthesis by activating the CD44/Smad3 pathway in fibroblasts. Both urine C3a and suPAR were increased and bound to the tubular cells in FSGS patients. C3a promoted the transcription of versican by activating the AKT/β-catenin pathway. C3aR knockout decreased the expression of versican in Adriamycin-treated (ADR-treated) mice. On the other hand, suPAR bound to integrin β6 and activated Rac1, which bound to SRp40 at the 5′ end of exon 7 in versican pre-mRNA. This binding inhibited the 3′-end splicing of intron 6 and the base-pair interactions between intron 6 and intron 8, leading to the formation of versican V1. Cotreatment with ADR and suPAR specifically increased the level of versican V1 in tubulointerstitial tissues and caused more obvious interstitial fibrosis in mice than treatment with only ADR. Altogether, our results show that C3a and suPAR drive versican V1 expression in tubular cells by promoting transcription and splicing, respectively, and the increases in tubular cell–derived versican V1 induce interstitial fibrosis by activating fibroblasts in FSGS.

Authors

Runhong Han, Shuai Hu, Weisong Qin, Jinsong Shi, Qin Hou, Xia Wang, Xiaodong Xu, Minchao Zhang, Caihong Zeng, Zhihong Liu, Hao Bao

×

Original citation: JCI Insight. 2019;4(7):e122912. https://doi.org/10.1172/jci.insight.122912

Citation for this corrigendum: JCI Insight. 2019;4(13):e130986. https://doi.org/10.1172/jci.insight.130986

The affiliations were incorrect. The correct author list and affiliations are below.

Runhong Han,1,2 Shuai Hu,2 Weisong Qin,2 Jinsong Shi,2 Qin Hou,2 Xia Wang,2 Xiaodong Xu,2 Minchao Zhang,2 Caihong Zeng,2 Zhihong Liu,1,2 and Hao Bao1,2

1Southeast University School of Medicine, National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing, China. 2National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.

The authors regret the errors.

Footnotes

See the related article at C3a and suPAR drive versican V1 expression in tubular cells of focal segmental glomerulosclerosis.

Version history
  • Version 1 (July 11, 2019): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Footnotes
  • Version history
Advertisement
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts